Maynard Um
-
-
-
-
-
-
-
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
-
-
-
-
-
-
-
Rhelion Life Sciences Reports First Quarter 2027 Results
-
-
-
-
-
-
-
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
-
-
-
-
-
-
-
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
-
-
-
-
-
-
-
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechani
-
-
-
-
-
-
-
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
-
-
-
-
-
-
-
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
-
456,130 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

